Independent Director · Acrivon Therapeutics, Inc. (ACRV)

Chair, Audit Committee

Michael Tomsicek, M.B.A — Acrivon Therapeutics Director Compensation (2025)

Fiscal year 2025 director compensation for Michael Tomsicek, M.B.A at Acrivon Therapeutics, Inc.. Every figure below is printed as the company filed it and cited to the filing it came from.

Director compensation as of the proxy filed April 30, 2026 (DEF 14A). Open the filing on EDGAR.

Free

Get Michael Tomsicek, M.B.A’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Michael Tomsicek, M.B.A and every company like it: Velarion Intel, free for 3 days, no card →

What they were paid

Acrivon Therapeutics Director Compensation Table · all 3 fiscal years held
In US dollars, as Acrivon Therapeutics reports it. Most recent year first. Totals are the company’s disclosed totals.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$55,000—$17,870$0$72,870
FY2024$58,750$0$92,286$0$151,036
FY2023$68,125$0$0—$68,125

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Acrivon Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001193125-26-194206, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Acrivon Therapeutics, Inc. filed document, accession 0001193125-26-194206. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

Get the Acrivon Therapeutics Board Governance Report

$72,870 Michael Tomsicek, M.B.A, FY2025 total director compensation

$500

The free page is the headline figures. The board report is director pay, board composition and committee fees combined into the same kind of document.

Data as of April 30, 2026 · Source: Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).

How this board is paid

company policy · FY2025

Acrivon Therapeutics pays directors a $40,000 cash retainer and $210,000 in Options.

Committees

FY2025 · as the proxy prints them

Audit (Chair)

The rest of the Acrivon Therapeutics board

FY2025 · as the company reported each
DirectorRoleFY2025 total
Charles Baum, M.D., Ph.DIndependent Director$77,870
Derek DiRocco, Ph.DIndependent Director$70,370
Ivana Magovčević-Liebisch, Ph.D., J.DIndependent Director$65,370
Kristina Masson, Ph.D., M.B.ADirector—
Peter Blume-Jensen, M.D., Ph.DChair of the Board—
Santhosh Palani, Ph.D., CFAIndependent Director$118,308
Sharon Shacham, Ph.D., M.B.AIndependent Director$65,370

The full Acrivon Therapeutics compensation record

free company brief

This page is one director within Acrivon Therapeutics's record. The company brief lists every named executive and director, each linking to their own page.

Order ACRV

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Board Governance Report